---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-22-303275"
form_type: "8-K"
ticker: "DNTH"
cik: "0001690585"
company_name: "Dianthus Therapeutics, Inc. /DE/"
filed_at: "2022-12-13T23:59:59+00:00"
generated_at: "2026-06-21T05:29:43.279084+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Magenta reports MGTA-117 Phase 1/2 data: no DLTs, two patients became transplant eligible

## Summary
- MGTA-117 showed dose-dependent binding and depletion of CD117+ cells; no dose-limiting toxicities observed in 15 patients across Cohorts 1-3.
- Two relapsed/refractory AML/MDS patients became eligible for transplant after a single dose of MGTA-117.
- Phase 1/2 trial currently enrolling Cohort 4 (0.13 mg/kg); aggregate data including Cohort 4 expected Q1 2023.
- Company plans to transition MGTA-117 into transplant-eligible AML/MDS patients in H1 2023 pending regulatory alignment.
- MGTA-145 Phase 2 trial in sickle cell disease data now expected H1 2023 due to enrollment delays.

## SEC filing metadata
- accession: 0001193125-22-303275
- form_type: 8-K
- ticker: DNTH
- cik: 0001690585
- company_name: Dianthus Therapeutics, Inc. /DE/
- filed_at: 2022-12-13T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 5.03, 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1690585/000119312522303275/0001193125-22-303275-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1690585/000119312522303275/d434402d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-22-303275
- JSON: https://secwatch.observer/filing/0001193125-22-303275.json
- Plain text: https://secwatch.observer/filing/0001193125-22-303275.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.